Press release
Hyperkalemia Therapeutics - Pipeline Analysis 2018 | Ardelyx, Inc., Relypsa
Download the sample report @ https://www.pharmaproff.com/request-sample/1155
The main causes of hyperkalemia are potassium sifting out of cells into the blood circulation, adrenal gland diseases, kidney dysfunction, uncontrolled diabetes, breakdown of muscle tissue and red blood cells. Hyperkalemia causes abnormal heart rhythms and also interferes in the functioning of the skeletal muscles. The common symptoms associated with the hyperkalemia are fatigue, nausea, muscle weakness and tingling sensations.
Get the detailed analysis @ https://www.pharmaproff.com/report/hyperkalemia-therapeutics-pipeline-analysis
The standard treatment strategies for hyperkalemia are intravenous administration of glucose and insulin, a diet low in potassium, medications that stimulate beta-2 adrenergic receptors, sodium bicarbonate administration and discontinue medications that increase blood potassium levels. Ardelyx Inc. is developing RDX013 which acts as a potassium secretagogue for the treatment of hyperkalemia. Relypsa Inc. is another key player involved in the development of drugs for the treatment of hyperkalemia.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1155
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperkalemia Therapeutics - Pipeline Analysis 2018 | Ardelyx, Inc., Relypsa here
News-ID: 1724272 • Views: …
More Releases for Ardelyx
Short Bowel Syndrome Market Deep Research 2025-2032 | Ardelyx, Inc., Emmaus Life …
The Global Short Bowel Syndrome Market is expected to grow at CAGR 21.6% from 2025 to 2032.
The Latest comprehensive Research Report on the Short Bowel Syndrome Market 2025-2032, Outlook is performed by determining industry drivers, dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. The Short Bowel Syndrome Market report has…
Hyperkalemia Treatment Market Moving in the Right Direction: AstraZeneca, Ardely …
The latest study released on the Global Hyperkalemia Treatment Market by HTF MI Research evaluates market size, trend, and forecast to 2030. The Hyperkalemia Treatment market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
Hyperphosphatemia Market to Witness Upsurge in Growth During the Forecast Period …
DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast
https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Hyperphosphatemia…
Investigation for Investors in NASDAQ: ARDX shares over possible Wrongdoing at A …
An investigation was announced for current long-term investors in shares of Ardelyx, Inc. (NASDAQ: ARDX) was announced over potential breaches of fiduciary duties by certain officers and directors at Ardelyx, Inc.
Investors who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Ardelyx, Inc. directors breached their fiduciary…
Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit filed against Di …
An investor in shares of Ardelyx, Inc. (NASDAQ: ARDX) filed a lawsuit against certain directors of Ardelyx, Inc over alleged breaches of fiduciary duties.
Investors who are current long term investors in Ardelyx, Inc. (NASDAQ: ARDX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff alleges that certain directors engaged in insider trading and made false and misleading statements about…
Lawsuit filed for Investors in shares of Ardelyx, Inc. (NASDAQ: ARDX)
An investor, who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX), filed a lawsuit over alleged violations of Federal Securities Laws by Ardelyx, Inc.
Investors who purchased shares of Ardelyx, Inc. (NASDAQ: ARDX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 28, 2021. NASDAQ: ARDX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Fremont, CA based Ardelyx, Inc., a biopharmaceutical…
